FDA approves Nemluvio for moderate-to-severe atopic dermatitis
The U.S. Food and Drug Administration has approved Galderma's Nemluvio (nemolizumab) for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older.
The Healthy on MSN5d
12 Silent Signs of Skin Cancer You’re Probably Ignoring
Dermatologists recommend that you do a monthly self-check of your moles and any other skin abnormalities to help catch ...